US Markets
Home›US Markets›Sectors›FDA advisers back compounding six popular peptides, wi…
FDA advisers back compounding six popular peptides, widening access
The panel’s discussion included concerns raised by industry ties and patient-safety considerations before recommending compounding of six peptides.
MarketWatch reports that a panel of Food and Drug Administration advisers said the FDA should allow six popular peptides to be compounded.
According to MarketWatch, the experts argued the change could widen access to the wellness products among Americans, though the deliberations also covered issues the panel considered in making the recommendation.
MarketWatch adds that some advisers have ties to the peptide industry, a factor that shaped how the group weighed the proposal.
← Newer storyForeclosure activity rises 21% year over year but stays in normal ris…Older story →Binary options brokers compete on fast execution, regulated access